Systemic delivery of phagocytosis-shielded retroviral vectors enables in vivo HSC gene therapy for sickle cell disease

Cell Stem Cell · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles